Walter P. Carney

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.